ID

19423

Beschrijving

GALLANT 8 Tesaglitazar Add-on to Metformin; ODM derived from: https://clinicaltrials.gov/show/NCT00251953

Link

https://clinicaltrials.gov/show/NCT00251953

Trefwoorden

Versies (1)
  1. 30-12-16 30-12-16 -
Geüploaded op

30 december 2016

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Type 2 Diabetes NCT00251953

Engels

Eligibility Type 2 Diabetes NCT00251953

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
provision of a written informed consent
Beschrijving

Informed Consent

Datatype

boolean

Alias
UMLS CUI [1]
C0021430
men or women who are >=18 years of age
Beschrijving

Age

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control
Beschrijving

Gender | Postmenopausal | Hysterectomy | Childbearing Potential Contraceptive methods

Datatype

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0232970
UMLS CUI [3]
C0020699
UMLS CUI [4,1]
C3831118
UMLS CUI [4,2]
C0700589
diagnosed with type 2 diabetes
Beschrijving

Diabetes Mellitus, Non-Insulin-Dependent

Datatype

boolean

Alias
UMLS CUI [1]
C0011860
treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents
Beschrijving

Diet therapy | Antidiabetic agent Oral Single | Antidiabetics Oral Quantity | Antidiabetics Oral Low dose

Datatype

boolean

Alias
UMLS CUI [1]
C0012159
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [2,3]
C0205171
UMLS CUI [3,1]
C0935929
UMLS CUI [3,2]
C1527415
UMLS CUI [3,3]
C1265611
UMLS CUI [4,1]
C0935929
UMLS CUI [4,2]
C1527415
UMLS CUI [4,3]
C0445550
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
type 1 diabetes
Beschrijving

Diabetes Mellitus, Insulin-Dependent

Datatype

boolean

Alias
UMLS CUI [1]
C0011854
new york heart association heart failure class iii or iv
Beschrijving

Heart failure New York Heart Association Classification

Datatype

boolean

Alias
UMLS CUI [1,1]
C0018801
UMLS CUI [1,2]
C1275491
treatment with chronic insulin
Beschrijving

Insulin regime chronic

Datatype

boolean

Alias
UMLS CUI [1,1]
C0557978
UMLS CUI [1,2]
C0205191
history of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like actos or avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor (statin)
Beschrijving

Hypersensitivity Peroxisome Proliferator-Activated Receptors | intolerance to Peroxisome Proliferator-Activated Receptors | Hypersensitivity Actos | Hypersensitivity Avandia | Fenofibrate allergy | Metformin allergy | Hypersensitivity Hydroxymethylglutaryl-CoA Reductase Inhibitors | intolerance to Actos | intolerance to Avandia | intolerance to Fenofibrate | intolerance to Metformin | intolerance to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Datatype

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0166418
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C0166418
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0875954
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0875967
UMLS CUI [5]
C0571869
UMLS CUI [6]
C0571648
UMLS CUI [7,1]
C0020517
UMLS CUI [7,2]
C0360714
UMLS CUI [8,1]
C1744706
UMLS CUI [8,2]
C0875954
UMLS CUI [9,1]
C1744706
UMLS CUI [9,2]
C0875967
UMLS CUI [10,1]
C1744706
UMLS CUI [10,2]
C0033228
UMLS CUI [11,1]
C1744706
UMLS CUI [11,2]
C0025598
UMLS CUI [12,1]
C1744706
UMLS CUI [12,2]
C0360714
history of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
Beschrijving

Drug-induced myopathy | Elevated creatine kinase Drug-induced | Elevated liver enzymes Drug-induced | Neutropenia Drug-induced

Datatype

boolean

Alias
UMLS CUI [1]
C0410220
UMLS CUI [2,1]
C0151576
UMLS CUI [2,2]
C0458082
UMLS CUI [3,1]
C0235996
UMLS CUI [3,2]
C0458082
UMLS CUI [4,1]
C0027947
UMLS CUI [4,2]
C0458082
creatinine levels above twice the normal range
Beschrijving

Serum creatinine raised

Datatype

boolean

Alias
UMLS CUI [1]
C0700225
creatine kinase above 3 times the upper limit of normal
Beschrijving

Elevated creatine kinase

Datatype

boolean

Alias
UMLS CUI [1]
C0151576
received any investigational product in other clinical studies within 12 weeks
Beschrijving

Study Subject Participation Status | Investigational New Drugs

Datatype

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
Beschrijving

Abnormality Clinical Significance Affecting Patient safety | Abnormality Clinical Significance Limiting Study Subject Participation Status | Physical Examination | Laboratory Procedures | Electrocardiography

Datatype

boolean

Alias
UMLS CUI [1,1]
C1704258
UMLS CUI [1,2]
C2826293
UMLS CUI [1,3]
C0392760
UMLS CUI [1,4]
C1113679
UMLS CUI [2,1]
C1704258
UMLS CUI [2,2]
C2826293
UMLS CUI [2,3]
C0439801
UMLS CUI [2,4]
C2348568
UMLS CUI [3]
C0031809
UMLS CUI [4]
C0022885
UMLS CUI [5]
C1623258
Terug naar het begin van de pagina

Similar models

Eligibility Type 2 Diabetes NCT00251953

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
provision of a written informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
men or women who are >=18 years of age
boolean
C0001779 (UMLS CUI [1])
Gender | Postmenopausal | Hysterectomy | Childbearing Potential Contraceptive methods
Item
female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control
boolean
C0079399 (UMLS CUI [1])
C0232970 (UMLS CUI [2])
C0020699 (UMLS CUI [3])
C3831118 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
Diabetes Mellitus, Non-Insulin-Dependent
Item
diagnosed with type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Diet therapy | Antidiabetic agent Oral Single | Antidiabetics Oral Quantity | Antidiabetics Oral Low dose
Item
treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents
boolean
C0012159 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0205171 (UMLS CUI [2,3])
C0935929 (UMLS CUI [3,1])
C1527415 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C0935929 (UMLS CUI [4,1])
C1527415 (UMLS CUI [4,2])
C0445550 (UMLS CUI [4,3])
Item Group
C0680251 (UMLS CUI)
Diabetes Mellitus, Insulin-Dependent
Item
type 1 diabetes
boolean
C0011854 (UMLS CUI [1])
Heart failure New York Heart Association Classification
Item
new york heart association heart failure class iii or iv
boolean
C0018801 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
Insulin regime chronic
Item
treatment with chronic insulin
boolean
C0557978 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
Hypersensitivity Peroxisome Proliferator-Activated Receptors | intolerance to Peroxisome Proliferator-Activated Receptors | Hypersensitivity Actos | Hypersensitivity Avandia | Fenofibrate allergy | Metformin allergy | Hypersensitivity Hydroxymethylglutaryl-CoA Reductase Inhibitors | intolerance to Actos | intolerance to Avandia | intolerance to Fenofibrate | intolerance to Metformin | intolerance to Hydroxymethylglutaryl-CoA Reductase Inhibitors
Item
history of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like actos or avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor (statin)
boolean
C0020517 (UMLS CUI [1,1])
C0166418 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C0166418 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0875954 (UMLS CUI [3,2])
C0020517 (UMLS CUI [4,1])
C0875967 (UMLS CUI [4,2])
C0571869 (UMLS CUI [5])
C0571648 (UMLS CUI [6])
C0020517 (UMLS CUI [7,1])
C0360714 (UMLS CUI [7,2])
C1744706 (UMLS CUI [8,1])
C0875954 (UMLS CUI [8,2])
C1744706 (UMLS CUI [9,1])
C0875967 (UMLS CUI [9,2])
C1744706 (UMLS CUI [10,1])
C0033228 (UMLS CUI [10,2])
C1744706 (UMLS CUI [11,1])
C0025598 (UMLS CUI [11,2])
C1744706 (UMLS CUI [12,1])
C0360714 (UMLS CUI [12,2])
Drug-induced myopathy | Elevated creatine kinase Drug-induced | Elevated liver enzymes Drug-induced | Neutropenia Drug-induced
Item
history of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
boolean
C0410220 (UMLS CUI [1])
C0151576 (UMLS CUI [2,1])
C0458082 (UMLS CUI [2,2])
C0235996 (UMLS CUI [3,1])
C0458082 (UMLS CUI [3,2])
C0027947 (UMLS CUI [4,1])
C0458082 (UMLS CUI [4,2])
Serum creatinine raised
Item
creatinine levels above twice the normal range
boolean
C0700225 (UMLS CUI [1])
Elevated creatine kinase
Item
creatine kinase above 3 times the upper limit of normal
boolean
C0151576 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs
Item
received any investigational product in other clinical studies within 12 weeks
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Abnormality Clinical Significance Affecting Patient safety | Abnormality Clinical Significance Limiting Study Subject Participation Status | Physical Examination | Laboratory Procedures | Electrocardiography
Item
any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
boolean
C1704258 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
C0392760 (UMLS CUI [1,3])
C1113679 (UMLS CUI [1,4])
C1704258 (UMLS CUI [2,1])
C2826293 (UMLS CUI [2,2])
C0439801 (UMLS CUI [2,3])
C2348568 (UMLS CUI [2,4])
C0031809 (UMLS CUI [3])
C0022885 (UMLS CUI [4])
C1623258 (UMLS CUI [5])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial